KR20050110103A - Novel process for producing cefonicid intermediate - Google Patents
Novel process for producing cefonicid intermediate Download PDFInfo
- Publication number
- KR20050110103A KR20050110103A KR1020040034929A KR20040034929A KR20050110103A KR 20050110103 A KR20050110103 A KR 20050110103A KR 1020040034929 A KR1020040034929 A KR 1020040034929A KR 20040034929 A KR20040034929 A KR 20040034929A KR 20050110103 A KR20050110103 A KR 20050110103A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- salt
- amino
- sulfomethyltetrazol
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 title description 2
- 229960004489 cefonicid Drugs 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims abstract description 52
- 238000006243 chemical reaction Methods 0.000 claims abstract description 40
- 239000000376 reactant Substances 0.000 claims abstract description 31
- 239000002253 acid Substances 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003960 organic solvent Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 229910015900 BF3 Inorganic materials 0.000 claims abstract description 8
- 150000007514 bases Chemical class 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 15
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 claims description 5
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- -1 NH 4 Inorganic materials 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims 1
- 238000007086 side reaction Methods 0.000 abstract description 10
- 238000000746 purification Methods 0.000 abstract description 7
- NZOFZRYLYIWUFP-UHFFFAOYSA-N 5-sulfanylidene-2h-tetrazole-1-sulfonic acid Chemical compound OS(=O)(=O)N1NN=NC1=S NZOFZRYLYIWUFP-UHFFFAOYSA-N 0.000 abstract description 5
- 229930186147 Cephalosporin Natural products 0.000 abstract description 5
- 229940124587 cephalosporin Drugs 0.000 abstract description 5
- 150000001780 cephalosporins Chemical class 0.000 abstract description 5
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- NLDLXEAUMGUSPX-UHFFFAOYSA-N (5-sulfanylidene-2h-tetrazol-1-yl)methanesulfonic acid Chemical group OS(=O)(=O)CN1N=NN=C1S NLDLXEAUMGUSPX-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001983 dialkylethers Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- ATMROFNURATUIQ-XCGJVMPOSA-N (6r)-7-amino-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1C(C(N1C=1C(O)=O)=O)N)CC=1CSC1=NN=NN1CS(O)(=O)=O ATMROFNURATUIQ-XCGJVMPOSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OCVNGUJWXHSOTB-UHFFFAOYSA-N SC1=NN=NN1CS(=O)(=O)O.SC1=NN=NN1CS(=O)(=O)O Chemical compound SC1=NN=NN1CS(=O)(=O)O.SC1=NN=NN1CS(=O)(=O)O OCVNGUJWXHSOTB-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 229960002420 cefatrizine Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- 150000001782 cephems Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/0005—Single stave recurve bows
- F41B5/0026—Take-down or foldable bows
- F41B5/0052—Limbs
- F41B5/0057—Limbs characterised by the material
- F41B5/0068—Limbs characterised by the material laminated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2262/00—Composition or structural features of fibres which form a fibrous or filamentary layer or are present as additives
- B32B2262/10—Inorganic fibres
- B32B2262/106—Carbon fibres, e.g. graphite fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B3/00—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form
- B32B3/10—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material
- B32B3/12—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material characterised by a layer of regularly- arranged cells, e.g. a honeycomb structure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B5/00—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts
- B32B5/18—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by features of a layer of foamed material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B9/00—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00
- B32B9/04—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00 comprising such particular substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B9/046—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00 comprising such particular substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material of foam
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B9/00—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00
- B32B9/04—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00 comprising such particular substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B9/047—Layered products comprising a layer of a particular substance not covered by groups B32B11/00 - B32B29/00 comprising such particular substance as the main or only constituent of a layer, which is next to another layer of the same or of a different material made of fibres or filaments
Landscapes
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Cephalosporin Compounds (AREA)
Abstract
세팔로스포린계 항생제인 세포니시드의 중간체인 하기 화학식 1로 표시되는 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 및 그 염의 신규한 제조방법이 개시된다. 본 발명은 알칸설폰산 용매, 및 삼불화붕소 또는 그 착물의 존재하에서, 7-아미노세팔로스포란산 또는 그 염과 (5-머캅토-테트라졸-1-일)-설폰산 또는 그 염을 반응시키는 단계; 및 상기 반응물에 물, 유기용매 또는 이들의 혼합물, 및 염기성 화합물을 첨가하여 반응물을 결정화하는 단계를 포함한다. 본 발명의 제조방법은 반응의 수율이 높고 부반응이 적어 간단한 정제과정으로 고순도의 세포니시드 중간체를 제조할 수 있다.7-Amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cef-4-carboxylic acid represented by the following Chemical Formula 1, an intermediate of cephalosidide, a cephalosporin-based antibiotic, and its A novel process for preparing salts is disclosed. The present invention provides (5-mercapto-tetrazol-1-yl) -sulfonic acid or salts thereof in the presence of an alkanesulfonic acid solvent and boron trifluoride or a complex thereof. Reacting; And crystallizing the reactant by adding water, an organic solvent or a mixture thereof, and a basic compound to the reactant. In the production method of the present invention, the high yield of the cell nisid intermediate can be prepared by a simple purification process because the reaction yield is high and there are few side reactions.
[화학식 1][Formula 1]
Description
본 발명은 세팔로스포린계 항생제인 세포니시드(cefonicid) 중간체의 신규한 제조방법에 관한 것으로서, 더욱 상세하게는 반응의 수율이 높고 부반응이 적어 간단한 정제과정으로 고순도의 세포니시드 중간체 또는 그 염을 제조하는 방법에 관한 것이다.The present invention relates to a novel method for preparing a cefonicid intermediate, a cephalosporin antibiotic, and more particularly, a high purity cenisid intermediate or a salt thereof in a simple purification process due to high yield of reaction and low side reaction. It relates to a method of manufacturing.
세팔로스포린계 항생제는 병원성 박테리아에 의한 감염성 질환의 치료제로서, 특히 페니실린 등의 다른 항생제에 내성이 있는 박테리아에 의한 질환자 및 페니실린 과민성 질환자를 치료하는데 유용한 항생제이다. 그동안 세펨환(cephem ring)의 3번기 또는 7번기에 다양한 치환기를 도입하여, 기존의 항생제에 대해 내성을 지닌 박테리아 또는 보다 넓은 범위의 박테리아에 의한 질환을 치료하기 위한 세팔로스포린계 항생제가 개발되어져 왔으며, 그 예로는 세파졸린, 세파제돈, 세포페라존, 세파만돌, 세파트리진, 세프트리악손, 세포니시드 등이 있다. 이러한 항생제는 그 용도가 동물 및 인체에 투입되어 질환을 치료하는 것이므로, 그 순도가 높아야 하는데, 종래의 제조방법은 부생성물이 많아 수율이 낮고, 정제후에도 최종생성물의 순도가 낮거나 순도가 높더라도 다수의 정제단계를 거쳐야 하므로 경제성이 저하되는 문제점이 있다.Cephalosporin-based antibiotics are therapeutic agents for infectious diseases caused by pathogenic bacteria, and are particularly useful for treating diseases caused by bacteria that are resistant to other antibiotics such as penicillin and penicillin hypersensitivity. Meanwhile, cephalosporin antibiotics have been developed to treat diseases caused by bacteria that are resistant to conventional antibiotics or a wider range of bacteria by introducing various substituents at the 3 or 7 of the cephem ring. Examples include cephazolines, cephazedone, cepharazone, cephamandol, cephatrizin, ceftriaxone, cenisidide and the like. Since these antibiotics are used in animals and humans to treat diseases, the purity of the antibiotics should be high. However, the conventional manufacturing method has a high yield because of a large number of by-products, and even after purification, the purity of the final product is low or high. Since a number of purification steps must be performed, there is a problem that the economic efficiency is lowered.
특히, 세팔로스포린계 항생제의 일종인 세포니시드의 제조방법으로서, 통상적으로 알려진 방법으로는, 중성 또는 약염기성의 물/유기용매 혼합액의 존재 하에서, 7-아미노세팔로스포란산(7-amino cephalosporanic acid)과 (5-머캅토-테트라졸-1-일)-메탄설폰산(5-mercapto-tetrazol-1-yl-methane sulfonic acid)을 반응시켜 7-아미노세팔로스포란산의 3번기에 아세톡시기 대신 (5-머캅토-테트라졸-1-일)-메탄설폰산기을 도입하여 세포니시드의 중간체를 제조하는 방법이 개시되어 있으나(미국특허 제4048311호, 제4159373호), 상기 방법은 반응 완결 후, 다량의 7-아미노세팔로스포란산이 미반응하여 잔존함은 물론, 부반응으로 인한 불순물이 많고, 복잡한 정제과정을 거쳐야 하는 문제점이 있다. 또한 상기 문제점을 보완하기 위하여 아세토니트릴(acetonitrile), 니트로메탄(nitro methane), 초산(acetic acid) 등의 유기용매, 및 삼불화붕소(boran trifluoride) 또는 그 착물(complex) 등 루이스산의 존재하에서 상기 반응물을 반응시켜 세포니시드의 중간체를 제조하는 방법이 개시되어 있으나(미국특허 제4317907호), 여전히 반응의 수율이 낮고, 부반응으로 인한 부생성물이 많아, 고성능 액체크로마토그래피(high performance liquid chromatography: HPLC) 등을 사용하여 정제하여야 하므로 경제성이 저하된다는 문제점이 있다.In particular, a method of producing cenisid, which is a kind of cephalosporin-based antibiotics, is a conventionally known method, which includes 7-aminocephalosporonic acid (7-) in the presence of a neutral or weakly basic water / organic solvent mixture solution. amino cephalosporanic acid) and (5-mercapto-tetrazol-1-yl) -methanesulfonic acid (5-mercapto-tetrazol-1-yl-methane sulfonic acid) to react 3 A method of preparing an intermediate of cenisid by introducing (5-mercapto-tetrazol-1-yl) -methanesulfonic acid group instead of acetoxy group is disclosed (US Pat. No. 4,031,111,4159373). After the completion of the reaction, a large amount of 7-aminocephalosporranic acid remains unreacted, as well as a lot of impurities due to side reactions, there is a problem to undergo a complicated purification process. In addition, in order to solve the above problems, in the presence of an organic solvent such as acetonitrile, nitro methane, acetic acid, and Lewis acid such as borane trifluoride or a complex thereof. Although a method of preparing an intermediate of ceniside by reacting the reactants is disclosed (US Pat. No. 4,397,907), the yield of the reaction is still low, and there are many by-products due to side reactions, and thus high performance liquid chromatography There is a problem that the economical efficiency is lowered because it must be purified by using HPLC).
따라서 본 발명의 목적은 반응의 수율이 높고 부반응이 적어 고순도의 세포니시드 중간체 또는 그 염을 제조하는 방법을 제공하는 것이다. 본 발명의 또다른 목적은 간단한 정제과정만으로 고순도의 세포니시드 중간체 또는 그 염을 제조하는 방법에 관한 것이다. Accordingly, an object of the present invention is to provide a method for producing a high purity cenisid intermediate or salt thereof due to high reaction yield and low side reaction. Another object of the present invention relates to a method for preparing high purity cenisid intermediate or salt thereof by simple purification.
상기 목적을 달성하기 위하여, 본 발명은 알칸설폰산(alkane sulfonic acid) 용매, 및 삼불화붕소 또는 그 착물의 존재하에서, 하기 화학식 2로 표시되는 7-아미노세팔로스포란산 또는 그 염과 하기 화학식 3으로 표시되는 (5-머캅토-테트라졸-1-일)-설폰산 또는 그 염을 반응시키는 단계; 및 상기 반응물에 물, 유기용매 또는 이들의 혼합물, 및 염기성 화합물을 첨가하여 반응물을 결정화하는 단계를 포함하는, 하기 화학식 1로 표시되는 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산(7-amino-3-[1-sulfomethyltetrazol-5ylthiomethyl] -3-cephem-4-carboxylic acid) 및 그 염의 제조방법을 제공한다.In order to achieve the above object, the present invention, in the presence of alkane sulfonic acid solvent, and boron trifluoride or a complex thereof, 7-aminocephalosporranic acid represented by the following formula (2) or salts thereof Reacting (5-mercapto-tetrazol-1-yl) -sulfonic acid or a salt thereof represented by Chemical Formula 3; And crystallizing the reactant by adding water, an organic solvent or a mixture thereof, and a basic compound to the reactant, 7-amino-3- [1-sulfomethyltetrazole-5- It provides a 7-amino-3- [1-sulfomethyltetrazol-5ylthiomethyl] -3-cephem-4-carboxylic acid) and a method for preparing the salt thereof.
상기 화학식 1 내지 3에서, R1 및 R2는 각각 독립적으로 H, Na, K, NH4, Ca 또는 Li이다.In Formulas 1 to 3, R 1 and R 2 are each independently H, Na, K, NH 4 , Ca, or Li.
이하 본 발명을 더욱 상세하게 설명하면 다음과 같다.Hereinafter, the present invention will be described in more detail.
본 발명에 따른 상기 화학식 1로 표시되는 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 및 그 염을 제조하기 위해서는, 먼저 하기 반응식 1에 나타낸 바와 같이, 알칸설폰산 용매, 및 삼불화붕소 또는 그 착물의 존재 하에서, 상기 화학식 2로 표시되는 7-아미노세팔로스포란산 또는 그 염과 상기 화학식 3으로 표시되는 (5-머캅토-테트라졸-1-일)-설폰산 또는 그 염을 반응시킨다.In order to prepare 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cefe-4-carboxylic acid and salts thereof represented by Chemical Formula 1 according to the present invention, As shown in Scheme 1, in the presence of an alkanesulfonic acid solvent and boron trifluoride or a complex thereof, 7-aminocephalosporranic acid represented by Formula 2 or a salt thereof and a compound represented by Formula 3 above (5- Mercapto-tetrazol-1-yl) -sulfonic acid or salt thereof is reacted.
상기 화학식 2로 표시되는 7-아미노세팔로스포란산 또는 그 염은 본 발명에 따른 상기 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산을 제조하기 위한 출발물질로서, 세펨환의 7번기인 아미노기(amino group)가 염산, 황산, p-톨루엔설폰산(p-toluenesulfonic acid), 메탄설폰산(methanesulfonic acid) 등의 산과 반응하여 생성되는 염을 포함할 수 있다.7-Aminocephalosporranic acid represented by the formula (2) or a salt thereof according to the present invention is the 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cefe-4- As a starting material for preparing a carboxylic acid, the amino group, the seventh group of the cefe ring, is reacted with an acid such as hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, and methanesulfonic acid. Salts produced.
상기 화학식 3으로 표시되는 (5-머캅토-테트라졸-1-일)-설폰산 또는 그 염은, 상기 화학식 2로 표시되는 7-아미노세팔로스포란산 또는 그 염의 세펨환의 3번기인 아세톡시기와의 치환반응으로 상기 3번기에 도입되는 반응물로서, 테트라졸환(tetrazole ring)의 1번기인 메틸설폰기(-SO3R1)와 5번기인 티올기(-R2S)의 R1 및 R2가 각각 독립적으로 수소, 또는 나트륨, 칼륨, 칼슘, 리튬 등의 1족 또는 2족 금속, 또는 암모늄(NH4)일 수 있다.(5-mercapto-tetrazol-1-yl) -sulfonic acid or its salt represented by the above formula (3) is 7-aminocephalosporranic acid represented by the above formula (2) or the 3rd group of the cefem ring of the salt thereof as reactant to be introduced into said three-Devonian the substitution reaction of methoxy groups, R 1 of tetra jolhwan 1 Devonian methyl sulfonic groups (-SO 3 R 1) and 5 Devonian a thiol group (-R 2 S) in (tetrazole ring) And R 2 may each independently be hydrogen or a Group 1 or Group 2 metal such as sodium, potassium, calcium, lithium, or ammonium (NH 4 ).
상기 알칸설폰산 용매는, 상기 반응의 반응용매 역할을 하는 것으로서, 탄소수 1 내지 2 개의 저급 알칸설폰산을 제한 없이 사용할 수 있으며, 바람직하게는 메탄설폰산을 사용할 수 있다. 상기 알칸설폰산을 용매로 사용하면, 물, 물/유기용매의 혼합물, 또는 아세토니트릴, 니트로메탄, 초산 또는 이들의 혼합물을 반응용매로서 사용하는 것에 비해 반응의 수율을 높이고, 부반응을 저하시켜 최종생성물의 순도를 향상시킬 수 있다.The alkanesulfonic acid solvent, which serves as a reaction solvent of the reaction, may be used without limitation to lower carbon alkanesulfonic acid having 1 to 2 carbon atoms, preferably methanesulfonic acid may be used. When the alkanesulfonic acid is used as the solvent, the yield of the reaction is increased and the side reactions are lowered compared to using water, a mixture of water / organic solvent, or acetonitrile, nitromethane, acetic acid, or a mixture thereof as a reaction solvent. Purity of the product can be improved.
상기 삼불화붕소 또는 그 착물은 상기 반응에 있어서 루이스산으로 작용하여 반응의 수율을 더욱 개선하는 역할을 하는 것으로서, 통상적으로 사용되는 삼불화붕소 또는 그 착물을 제한 없이 사용할 수 있으며, 비한정적으로는 디알킬에테르(dialkyl ether)와의 착염, 아민(amines)과의 착염, 초산 등의 지방족산(aliphatic acid)과의 착염, 니트릴(nitriles)과의 착염, 카르복실에스테르와의 착염을 예시할 수 있으며, 바람직하게는 디알킬에테르와의 착염인 삼불화붕소 디에틸에테르를 사용할 수 있다.The boron trifluoride or a complex thereof acts as a Lewis acid in the reaction to further improve the yield of the reaction, and can be used without limitation, boron trifluoride or a complex that is commonly used, without limitation Complex salts with dialkyl ethers, salts with amines, salts with aliphatic acids such as acetic acid, salts with nitriles, and salts with carboxyl esters. And boron trifluoride diethyl ether, which is preferably a complex salt with a dialkyl ether, can be used.
상기 화학식 3으로 표시되는 (5-머캅토-테트라졸-1-일)-설폰산 또는 그 염의 함량은 상기 화학식 2로 표시되는 7-아미노세팔로스포란산 또는 그 염 1몰에 대하여 1몰 내지 3몰인 것이 바람직하며, 더욱 바람직하게는 1 내지 1.5몰을 사용할 수 있다. 1몰 미만이면 반응이 완결되지 않고, 3몰을 초과하면 과량의 투입에 따른 미반응물의 부반응으로 인하여 부생성물이 다량 생김으로서, 생성물의 수율 및 순도가 저하될 염려가 있다. 상기 알칸설폰산의 함량은 7-아미노세팔로스포란산 또는 그 염 1몰에 대하여 5 내지 20몰인 것이 바람직하다. 만일 5몰 미만이면 반응성이 저하될 염려가 있고, 20몰을 초과하면 반응의 완결 후, 반응물을 정제하기 위한 중화 반응에 사용되는 암모니아수 등의 염기성 화합물의 사용량의 증가로 반응물의 순도가 저하되는 문제가 있다. 삼불화붕소 또는 그 착물의 함량은 7-아미노세팔로스포란산 또는 그 염 1몰에 대하여 5 내지 10몰인 것이 바람직하다. 만약 5몰 미만이면 반응속도가 늦어 공정시간이 길어지고, 부반응으로 인한 부생성물이 증가하여 반응물의 수율이 저하되며, 10몰을 초과하면 반응물을 정제하기 위한 중화 반응에 사용되는 암모니아수 등의 염기성 화합물의 사용량의 증가로 반응물의 순도가 저하되는 문제점이 있다.The content of (5-mercapto-tetrazol-1-yl) -sulfonic acid or salt thereof represented by Formula 3 is 1 mol relative to 1 mol of 7-aminocephalosporranic acid or salt thereof represented by Formula 2 above. It is preferable that it is 1-3 mol, More preferably, 1-1.5 mol can be used. If the amount is less than 1 mole, the reaction is not completed. If the amount is more than 3 mole, a large amount of by-products are generated due to side reactions of the unreacted substances due to the excessive input, which may lower the yield and purity of the product. The content of the alkanesulfonic acid is preferably 5 to 20 moles with respect to 1 mole of 7-aminocephalosporanic acid or salts thereof. If less than 5 moles, the reactivity may be lowered. If more than 20 moles, after completion of the reaction, the purity of the reactants may be lowered due to an increase in the amount of basic compounds such as ammonia water used in the neutralization reaction for purifying the reactants. There is. It is preferable that the content of boron trifluoride or its complex is 5-10 mol with respect to 1 mol of 7-amino cephalosporranic acid or its salt. If the amount is less than 5 moles, the reaction rate is slow, and the process time is long, and the by-products from the side reactions increase, and the yield of the reactants is reduced. There is a problem in that the purity of the reactants is lowered due to the increase in the amount of.
상기 반응으로 생성되는 상기 화학식 1로 표시되는 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 또는 그 염은 세펨환의 7번기인 아미노기가 염산, 황산, p-톨루엔설폰산, 메탄설폰산 등의 산과 반응하여 생성되는 염을 포함할 수 있다.The 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cef-4-carboxylic acid or salt thereof represented by Chemical Formula 1 produced by the reaction is the 7th group of the cefem ring. Amino groups may include salts produced by reaction with acids such as hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, methanesulfonic acid, and the like.
상기 반응은 -20 내지 80℃의 온도 및 상압 하에서, 20분 내지 5시간 동안 수행할 수 있다. 반응온도가 -20℃ 미만이거나 80℃를 초과하면 부반응으로 인한 부생성물의 증가로 반응물의 수율이 저하된다. 반응시간이 20분 미만이면 반응이 완결되지 않으며, 5시간을 초과하면 공정시간만 길어질 뿐 별다른 장점이 없다.The reaction may be performed at a temperature of −20 to 80 ° C. and atmospheric pressure for 20 minutes to 5 hours. If the reaction temperature is lower than -20 ° C or higher than 80 ° C, the yield of the reactants decreases due to an increase in byproducts due to side reactions. If the reaction time is less than 20 minutes, the reaction is not completed, if it exceeds 5 hours, only the process time is long, there is no particular advantage.
다음으로 반응이 완결된 후, 반응물에 물, 유기용매 또는 이들의 혼합물을 첨가한 후, 상기 용매가 첨가된 반응물에 염기성 화합물을 넣고, 30분 내지 3시간 동안 숙성시켜 상기 화학식 1로 표시되는 반응물인 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 또는 그 염을 결정화시킨다.Next, after completion of the reaction, water, an organic solvent or a mixture thereof is added to the reactants, a basic compound is added to the reactant to which the solvent is added, and the reactants represented by Chemical Formula 1 are aged for 30 minutes to 3 hours. Phosphorus 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cefe-4-carboxylic acid or salt thereof is crystallized.
상기 유기용매로는 통상적으로 사용하는 알코올계 화합물 등의 유기용매를 제한 없이 사용할 수 있으며, 비한정적인 예로는 메탄올, 에탄올, 이소프로판올, 프로판올, n-부탄올, 2-부탄올, 이소부탄올, t-부탄올, 아세톤, 테트라하이드로퓨란, 1,4-디옥산 및 이들의 혼합물을 예시할 수 있으며, 바람직하게는 무기염 등의 부생성물을 제거하여 반응물의 함량 및 순도가 저하되는 것을 막기 위해, 물과 알코올계 화합물의 혼합액을 사용할 수 있다. 상기 유기용매의 함량은 7-아미노 세팔로스포란산 또는 그 염 1g에 대해 1 내지 50ml인 부피/중량비(ml/g)인 것이 바람직하며, 10 내지 20 배의 부피/중량비이면 더욱 바람직하다. 1 부피/중량비 미만이면 반응물의 순도가 저하될 염려가 있고, 50부피/중량비를 초과하면 결정화속도가 느려 공정시간만 길어질 뿐 별다른 장점이 없다. 물/알코올계 화합물의 혼합비율은 어느 용매에 대해서도 다른 용매가 1 내지 50 부피비의 범위 내인 것이 바람직하고, 1 내지 10 부피비면 더욱 바람직하다. 상기 범위를 벗어나면 혼합의 효과가 미미하고, 특히 반응물의 수율 및 순도가 저하될 염려가 있다. As the organic solvent, organic solvents such as alcohol-based compounds that are commonly used may be used without limitation, and non-limiting examples include methanol, ethanol, isopropanol, propanol, n-butanol, 2-butanol, isobutanol, t-butanol , Acetone, tetrahydrofuran, 1,4-dioxane and mixtures thereof may be exemplified. Preferably, water and alcohols are removed to remove the by-products such as inorganic salts, thereby reducing the content and purity of the reactants. A mixed solution of a system compound can be used. The content of the organic solvent is preferably a volume / weight ratio (ml / g) of 1 to 50 ml with respect to 1 g of 7-amino cephalosporranic acid or a salt thereof, and more preferably 10 to 20 times the volume / weight ratio. If it is less than 1 volume / weight ratio, there is a concern that the purity of the reactant is lowered, and if it exceeds 50 volume / weight ratio, the crystallization rate is slow and only the process time is long, there is no particular advantage. It is preferable that the other solvent is in the range of 1-50 volume ratio with respect to any solvent, and, as for the mixing ratio of a water / alcohol type compound, it is more preferable if it is 1-10 volume ratio. Outside the above range, the effect of mixing is insignificant, in particular, there is a fear that the yield and purity of the reactants are lowered.
상기 염기성 화합물은 반응물의 수소이온농도(pH)를 조절하는 역할을 하는 것으로서, 상기 염기성 화합물로는 통상적으로 사용하는 것을 제한 없이 사용할 수 있고, 비한정적으로는 아민, 암모니아, 디에틸아민, 트리에틸아민 및 이들의 혼합물을 예시할 수 있으며, 바람직하게는 암모니아를 사용할 수 있다. 상기 염기성 화합물의 함량은 상기 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 또는 그 염의 결정화 속도 등의 결정화 조건에 의존하는데, 바람직하게는 반응물의 pH가 0 내지 7, 더욱 바람직하게는 1 내지 4가 되도록 사용할 수 있다. 만약 반응물의 pH가 상기 범위를 벗어나면 반응의 수율이 저하될 염려가 있다.The basic compound serves to control the hydrogen ion concentration (pH) of the reactants, and the basic compound can be used without limitation, conventionally used, without limitation, amine, ammonia, diethylamine, triethyl Amines and mixtures thereof can be exemplified, preferably ammonia. The content of the basic compound depends on crystallization conditions such as the crystallization rate of the 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cef-4-carboxylic acid or salts thereof, Preferably the pH of the reactants can be used to be 0 to 7, more preferably 1 to 4. If the pH of the reactants is out of the above range there is a fear that the yield of the reaction is lowered.
상기 결정화 단계는 세포니시드 중간체의 통상적인 결정화 공정 조건 하에서 수행할 수 있으며, 예를 들면 0℃의 온도 하에서, 2시간 동안 수행할 수 있다The crystallization step may be carried out under the usual crystallization process conditions of the cenisid intermediate, for example, at a temperature of 0 ℃, can be carried out for 2 hours.
또한, 필요에 따라 상기 결정화된 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 또는 그 염을 포함한 반응물을 여과한 후, 물, 유기용매 또는 이들의 혼합물로 세척하고, 건조하여 고순도의 상기 화학식 1로 표시되는 화합물인 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 또는 그 염을 제조할 수 있으며, 최종 목적물의 순도를 더욱 높이기 위하여, 액체크로마토그래피 등을 사용하여 최종생성물을 정제할 수도 있다. 상기 반응물의 세척은 상기 결정화 단계에서 사용할 수 있는 유기용매로서, 바람직하게는 메탄올 및 아세톤을 사용할 수 있으며, 일 예로서 반응물을 순차로 물, 메탄올 및 아세톤로 세척하여 수행할 수 있다.Further, if necessary, the reaction product containing the crystallized 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cef-4-carboxylic acid or salts thereof is filtered and then water , 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cef-4-, a compound represented by Chemical Formula 1, washed with an organic solvent or a mixture thereof and dried to obtain high purity. Carboxylic acids or salts thereof may be prepared, and the final product may be purified using liquid chromatography or the like to further increase the purity of the final target product. The washing of the reactant is preferably an organic solvent that can be used in the crystallization step, preferably methanol and acetone. For example, the reactant may be sequentially washed with water, methanol and acetone.
이하, 하기 실시예에 의하여 본 발명을 더욱 상세하게 설명하기로 하나, 본 발명의 범위가 하기 실시예에 의하여 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited by the following examples.
[실시예 1] 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 및 그 염류의 제조 Example 1 Preparation of 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cefe-4-carboxylic acid and salts thereof
반응기에 메탄설폰산 400ml 및 삼불화붕소 디에틸에테르 320ml를 넣고, 반응물의 온도를 0℃로 냉각시킨 후, 냉각된 반응물에 상기 화학식 2로 표시되는 7-아미노세팔로스포란산 100g 및 (5-머캅토-테트라졸-1-일)-메탄설폰산 84.4g을 첨가하여 4시간동안 반응을 수행하였다. 반응이 완결된 후, 반응물에 정제수 1500ml 및 메탄올 1500ml를 서서히 적가하고, 0℃에서, 상기 적가된 반응물에 암모니아수를 가하여 반응물의 pH를 2.0으로 하여 2시간 동안 반응물을 결정화하였고, 결정화된 반응물을 여과하였으며, 여과된 반응물을 순차적으로 물, 메탄올 및 아세톤으로 세척한 후, 건조하여 생성물인 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 148g을 얻었고(수율: 98.6%), 고성능 액체크로마토그래피를 사용하여 고순도의 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산을 제조하였다(순도: 99%이상). 400 ml of methanesulfonic acid and 320 ml of boron trifluoride diethyl ether were added to the reactor, and the temperature of the reactant was cooled to 0 ° C., and then 100 g of 7-aminocephalosporanic acid represented by the formula (2) and (5 The reaction was carried out for 4 hours by adding 84.4 g of -mercapto-tetrazol-1-yl) -methanesulfonic acid. After the reaction was completed, 1500 ml of purified water and 1500 ml of methanol were slowly added dropwise to the reaction, and at 0 ° C., ammonia water was added to the added reaction to crystallize the reactant for 2 hours at pH 2.0 of the reactant, and the crystallized reactant was filtered. The filtered reaction was washed sequentially with water, methanol and acetone, and then dried to give the product 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cefe-4-car 148 g of acid was obtained (yield: 98.6%), and high-purity 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cepem-4-carboxyl was obtained using high performance liquid chromatography. Acid was prepared (purity: 99% or more).
[비교예 1] 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 및 그 염류의 제조 Comparative Example 1 Preparation of 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cefe-4-carboxylic acid and salts thereof
반응기에 정제수 500ml, 및 중탄산나트륨 21.0g를 넣고, 상기 화학식 2로 표시되는 7-아미노세팔로스포란산 27.2g 및 정제수 500ml,와 아세톤 250ml의 혼합 용액을 첨가한 후, 반응물의 온도를 45℃로 올리고, (5-머캅토-테트라졸-1-일)-메탄설폰산 29.3g 및 아세톤 1000ml 혼합용액을 45℃를 유지하면서 서서히 적가하고, 반응물의 pH를 7.4 내지 7.6로 유지하면서 2시간동안 환류시키며 반응을 수행하였다. 반응이 완결된 후, 반응물을 0℃로 냉각하고, 냉각된 반응물에 묽은 염산을 가하여 반응물의 pH를 4.0으로 만든 후, 반응물을 결정화하였다. 결정화된 반응물을 여과하고, 여과된 반응물을 아세톤으로 세척한 후, 건조하여 생성물인 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 28.5g을 얻었고(수율: 70%), 고성능 액체크로마토그래피를 사용하여 고순도의 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산을 제조하였다(순도: 95%).500 ml of purified water and 21.0 g of sodium bicarbonate were added to the reactor, and a mixed solution of 27.2 g of 7-aminocephalosporanic acid represented by the formula (2), 500 ml of purified water, and 250 ml of acetone was added thereto, and the temperature of the reactant was 45 ° C. 29.3 g of (5-mercapto-tetrazol-1-yl) -methanesulfonic acid and 1000 ml of acetone were slowly added dropwise while maintaining the temperature at 45 ° C., and the reaction was maintained at 7.4 to 7.6 for 2 hours. The reaction was carried out at reflux. After the reaction was completed, the reaction was cooled to 0 ° C., diluted hydrochloric acid was added to the cooled reaction to bring the pH of the reaction to 4.0, and the reaction was crystallized. The crystallized reactant was filtered off, the filtered reactant was washed with acetone and dried to yield the product 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cepem-4-carboxyl. 28.5 g of acid were obtained (yield: 70%), and high-purity 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cef-4-carboxyl was obtained using high performance liquid chromatography. Acid was prepared (purity: 95%).
[비교예 2] 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 및 그 염류의 제조 Comparative Example 2 Preparation of 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cefe-4-carboxylic acid and salts thereof
반응기에 아세토니트릴 140ml, 상기 화학식 2로 표시되는 7-아미노세팔로스포란산 27.2g, (5-머캅토-테트라졸-1-일)-메탄설폰산 29.3g 및 삼불화붕소 디에틸에테르 42.6g을 순차적으로 넣고, 반응물의 온도를 50℃로 상승시킨 후, 2시간 동안 교반하면서 반응을 수행하였다. 반응이 완결된 후, 반응물을 0℃로 냉각시켰고, 냉각된 반응물에 정제수 140ml를 첨가하고, 암모니아수로 넣어 반응물의 pH를 4.0으로 만든 상태에서, 2시간 동안 반응물을 결정화시켰다. 결정화된 반응물을 여과하고, 아세톤으로 세척한 후 건조하여 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산 33g을 얻었고(수율: 81%), 고성능 액체크로마토그래피를 사용하여 고순도의 7-아미노-3-[1-설포메틸테트라졸-5-일티오메틸]-3-세펨-4-카르복실산을 제조하였다(순도: 92%). 140 ml of acetonitrile in the reactor, 27.2 g of 7-aminocephalosporanic acid represented by the formula (2), 29.3 g of (5-mercapto-tetrazol-1-yl) -methanesulfonic acid and 42.6 of boron trifluoride diethyl ether g was added sequentially and the temperature of the reaction was raised to 50 ° C., followed by stirring for 2 hours. After the reaction was completed, the reaction was cooled to 0 ° C., and 140 ml of purified water was added to the cooled reaction, and the reaction was crystallized for 2 hours while the pH of the reaction was adjusted to 4.0 by adding ammonia water. The crystallized reaction was filtered, washed with acetone and dried to give 33 g of 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cefe-4-carboxylic acid (yield: 81%), using high performance liquid chromatography to prepare high purity 7-amino-3- [1-sulfomethyltetrazol-5-ylthiomethyl] -3-cepem-4-carboxylic acid (purity: 92 %).
본 발명에 따른 세포니시드 중간체 또는 그 염의 제조방법은, 반응의 수율이 높고 부반응이 적어 고순도의 세포니시드 중간체 또는 그 염을 제조할 수 있는 장점이 있고, 또한 간단한 정제과정만으로 고순도의 세포니시드 중간체 또는 그 염을 경제적으로 제조할 수 있다는 장점이 있다.The method for producing a cell nisid intermediate or a salt thereof according to the present invention has the advantage of producing a high purity cell nisid intermediate or a salt thereof with high yield of reaction and less side reactions, and also a high purity cell nitrile by a simple purification process. There is an advantage that the seed intermediate or salt thereof can be economically prepared.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040034929A KR100589559B1 (en) | 2004-05-17 | 2004-05-17 | novel process for producing cefonicid intermediate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040034929A KR100589559B1 (en) | 2004-05-17 | 2004-05-17 | novel process for producing cefonicid intermediate |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050110103A true KR20050110103A (en) | 2005-11-22 |
KR100589559B1 KR100589559B1 (en) | 2006-06-14 |
Family
ID=37285670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040034929A KR100589559B1 (en) | 2004-05-17 | 2004-05-17 | novel process for producing cefonicid intermediate |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100589559B1 (en) |
-
2004
- 2004-05-17 KR KR1020040034929A patent/KR100589559B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR100589559B1 (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1562957B1 (en) | Process for the preparation of 3-propenyl cephalosporin dmf solvate | |
WO2004046154A1 (en) | Novel amorphous hydrate of a cephalosporin antibiotic | |
KR101109177B1 (en) | Penam crystal and process for producing the same | |
EP1813619B1 (en) | Process for producing penam compound | |
CN108084212B (en) | Preparation method of cefditoren pivoxil | |
KR100589559B1 (en) | novel process for producing cefonicid intermediate | |
CN108033971B (en) | Method for synthesizing cefcapene pivoxil hydrochloride | |
KR20020068517A (en) | Crystals of penicillin and process for the production thereof | |
KR100343434B1 (en) | Method of preparing 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid | |
CN108299470B (en) | Preparation method of cefteram pivoxil | |
US7476760B2 (en) | Purification and production methods of 1-aminocyclopropanecarboxylic acid | |
CN108017658B (en) | Synthesis method of cefprozil | |
CN111253405B (en) | Preparation method of biapenem intermediate | |
KR101170192B1 (en) | One-pot process for producing 1,2-benzisoxazole-3-methanesulfonamide | |
CN114805394A (en) | Synthesis method of cefixime | |
KR100477763B1 (en) | The Novel preparation of Intermediate of Cefatrizine Propylene gylcol | |
JP4529116B2 (en) | Method for producing high-purity tritylpiperazine derivative | |
KR100388108B1 (en) | New process for producing intermediates of cephalosporin antibiotics | |
KR100749163B1 (en) | Method for producing derivatives of 7?-methoxyoxacephem | |
JP3302417B2 (en) | Method for producing 3-alkoxymethyl-cephalosporin derivative | |
KR970004047B1 (en) | Novel process for the preparation of cephem compound | |
KR20120078687A (en) | Process for the preparation of cephalosporin intermediate using new enzyme | |
US20220041574A1 (en) | Pyrazole amine reactive crystallization | |
KR20110070523A (en) | Process for the preparation of cephalosporin intermediate using new enzyme | |
CN110878071A (en) | Preparation method of α -amino-gamma-butyrolactone and salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120601 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee |